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Background: Airway inﬂammation may drive the progression of chronic obstructive
pulmonary disease (COPD) associated with alpha-1 antitrypsin deﬁciency (AATD), but the
relationship between airway microbiota and inﬂammation has not been investigated.
Methods: We studied 21 non-treated AATD (AATD-noT) patients, 20 AATD-COPD
patients under augmentation therapy (AATD-AT), 20 cigarette smoke-associated COPD
patients, 20 control healthy smokers (CS) and 21 non-smokers (CON) with normal lung
function. We quantiﬁed sputum inﬂammatory cells and inﬂammatory markers (IL-27, CCL3,
CCL5, CXCL8, LTB4, MPO) by ELISA, total bacterial load (16S) and pathogenic bacteria
by qRT-PCR.
Results: AATD-AT patients were younger but had similar spirometric and DLCO values
compared to cigarette smoke-associated COPD, despite a lower burden of smoking history.
Compared to cigarette smoke-associated COPD, AATD-noT and AATD-AT patients had
lower sputum neutrophil levels (p=0.0446, p=0.0135), total bacterial load (16S) (p=0.0081,
p=0.0223), M. catarrhalis (p=0.0115, p=0.0127) and S. pneumoniae (p=0.0013, p=0.0001).
Sputum IL-27 was signiﬁcantly elevated in CS and cigarette smoke-associated COPD.
AATD-AT, but not AATD-noT patients, had IL-27 sputum levels (pg/ml) signiﬁcantly
lower than COPD (p=0.0297) and these positively correlated with FEV1% predicted values
(r=0.578, p=0.0307).
Conclusions: Compared to cigarette smoke-associated COPD, AATD-AT (COPD) patients
have a distinct airway inﬂammatory and microbiological proﬁle. The decreased sputum
bacterial load and IL-27 levels in AATD-AT patients suggests that augmentation therapy
play a role in these changes.
Keywords: alpha-1 antitrypsin deﬁciency, COPD, chronic airway inﬂammation, respiratory
disability, sputum
Introduction
Alpha-1 antitrypsin deﬁciency (AATD) is a genetic condition considered a risk factor
for developing chronic obstructive pulmonary disease (COPD).1 An increased bur-
den of neutrophils is characteristic of AATD lungs.2 AAT, which is coded by the
SERPINA1 gene (or Protease inhibitor-PI) is a serine protease inhibitor mainly
secreted by the hepatocytes whose major target is elastases but can also inhibit the
function of thrombin, trypsin, chymotrypsin, plasmin and plasminogen activator.2
In patients without AATD, neutrophilic pulmonary inﬂammation is considered
central to the development and progression of cigarette smoke-associated COPD.3–5
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Neutrophilic inﬂammation correlates with stable COPD
severity6,7 and it further increases during COPD
exacerbations.8,9 Neutrophil-related inﬂammatory mediators
such as leukotriene (LT)B4,
10 chemokine (C-X-C motif)
ligand 8 (CXCL-8, previously named interleukin-8), chemo-
kine ligand 3 [CCL3 also known as macrophage inﬂamma-
tory protein-1α (MIP-1α)],6 and chemokine ligand 5 [CCL5
also known as RANTES (regulated on activation, normal T
cell expressed and secreted)]11 are increased in the lower
airways of cigarette smoke-associated COPD patients parti-
cularly in subjects with stable severe disease.4 Increased
neutrophilia is also associated to increased levels of IL-27
protein in the lung of COPD patients.12 In patients with
COPD associated with AATD, the general functional and
inﬂammatory picture is worse when compared to cigarette
smoke-associated COPD of similar severity.2,10,13,14
A pathogenic role of bacterial load leading to bronchial
inﬂammation is implicated in cigarette smoke-associated
COPD.3,15–17 Augmentation therapy, ie weekly infusion of
exogenousAAT, in patientswith COPD associatedwith severe
AATD restores AAT levels to normal in blood, sputum and
bronchoalveolar lavage (BAL)18–20 slowing the progression of
the disease, 19–21 decreasing the number of exacerbations,22
and sputum neutrophil numbers, LTB4 levels and MPO
expression.14,23 The relationship between bacterial load and
sputum inﬂammation in patients with AATD, whether under
augmentation therapy or untreated, has not been studied.
The aim of the present study was to investigate the
total and speciﬁc bacterial load in sputum of patients with
COPD associated to AATD compared to patients with
cigarette smoke-associated COPD and control healthy
smokers and non-smokers with normal lung function, and
to correlate these data with inﬂammatory cells, cytokines
and physiological parameters.
Methods
Subjects
Twenty cigarette smoke-associated COPD patients, 20
COPD patients with alpha-1 antitrypsin deﬁciency
(AATD) in augmentation therapy (AATD-AT), 21 AATD
patients not in augmentation therapy (AATD-noT), 20
control smokers with normal lung function (CS) and 21
control non-smokers with normal lung function (CON)
who underwent sputum collection were recruited from
the Respiratory Medicine Unit of the Istituti Clinici
Scientiﬁci Maugeri’s Institute of Veruno, Institute of
Cassano delle Murge, IRCCS Policlinico S. Matteo,
Pavia (Italy), and from the Spedali Civili, Brescia (Italy),
and Pneumology Unit of Aosta (Italy). COPD was deﬁned,
according to international guidelines.1,13,24 Diagnostic cri-
teria for AATD were as from the current ATS/ERS
statement.1,13,24 Indications for AT are for patients with
severe AATD and compound heterozygotes or homozy-
gotes of deﬁcient/Null variants of SERPINA1 gene (not
only PI*ZZ but also PI*SZ, PI*Null/Null etc.) and with a
signiﬁcant airﬂow obstruction and in the context of general
disability and health impairment. In COPD patients and in
patients with AATD the severity of the airﬂow obstruction
was graded using current GOLD criteria.1,13,24 COPD and
AATD-AT patients had a FEV1/FVC ratio lower than 70%
of predicted values at post-bronchodilator spirometry and
absence of history and symptoms of asthma. In all
patients, the severity of emphysema was graded based on
high-resolution computed tomography (HRCT) scan radi-
ologic reports as follows: 0=absence of emphysema, 1=1–
25% of lung with emphysema, 2=26–50% of lung with
emphysema, 3=51–75% of lung with emphysema, 4=76–
100% of lung with emphysema. COPD patients and
patients with AATD with evidence of bronchiectasis13
were excluded. All former smokers had stopped smoking
from at least one year before inclusion in the study. All
COPD patients and AATD patients were stable with no
previous exacerbation in the three months before collec-
tion of the sputum. None of the subjects was treated with
theophylline, antibiotics, antioxidants, mucolytics, and/or
glucocorticoids in the three months prior sputum collec-
tion. Cigarette smoke-associated COPD patients and
patients with COPD and AATD were using short-acting
inhaled β2-agonists (SABA) and/or regular long-acting
inhaled β2- agonists (LABA) and/or regular inhaled
long-acting inhaled anti-muscarinics (LAMA) at the time
of their recruitment. AATD-AT patients had been under
augmentation therapy for at least three months. Subjects
were tested for peripheral blood levels of AAT and for
genetic analysis of SERPINA1 gene. Testing was per-
formed on dried blood spot samples at the National
Reference Center for AATD at the University of Pavia.
The study conformed to the Declaration of Helsinki and
was approved by the ethics committee of the Istituti
Clinici Scientiﬁci Maugeri SpA, Società Beneﬁt (n. 989
CE). (Protocol Registration: Clinical Trials.gov ID:
NCT02547532). Written informed consent was obtained
from each subject and sputum collection were performed
according to the local ethical committee guidelines.
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Sputum samples collection and processing
Spontaneous or induced sputum was obtained from all
study subjects. Induced sputum was obtained after inhala-
tion of hypertonic saline (4.5%) following international
guidelines.17,24 Sputum obtained from each subject was
processed by the use of dithiothreitol (1:1) to obtain a
liquid sputum specimen. This liquid sputum was divided
into 3 aliquots: 1) one aliquot was used for Colony
Forming Units (CFU) quantitation; 2) a second aliquot
was processed for cytospin and surnatant preparations.
May-Grunwald-Giemsa stained cytospins were used for
cell count and cellular type differentiation. In the cytospin
preparations a minimum number of 200 cells (range: 200–
300 cells for all cases) was counted for each subject. In all
cases squamous epithelial cells number was <80% of total
cells counted (squamous epithelial cells percentage for all
patient groups, mean±SD: 41.23±11.9). Supernatants were
used for ELISA analysis of secreted cytokines related to
innate immunity response and to neutrophilic activation
(CCL3, CCL5, CXCL8, IL-27, LTB4, MPO, Table S1); 3)
a third aliquot was used for bacterial RNA/DNA extraction
(Qiagen, Pathogen Mini Kit, Cat. N. 54104) and qRT-PCR
analysis. Bacterial analysis was performed using RT-PCR
and Syber Green technology.6,7,11,12 Bacterial analysis
included: total bacterial load (16S), Moraxella catarrhalis,
Haemophilus inﬂuenzae, Streptococcus pneumoniae, and
Staphylococcus aureus.7 Total bacterial load (16S) was
quantiﬁed after sputum RNA/DNA extraction. DNA stan-
dard for qRT-PCR was prepared from pure DNA cultures
of Escherichia coli to generate a standard curve. The
standard curve was performed in triplicate with regression
coefﬁcients close to 1 (range of R2 values: 0.984—0.994
for E. coli) and showed a linear increase within the range
of DNA concentration utilized, as previously reported.15
Genesig standard kits (Genesig Standard kit handbook
HB10.04.09, published date 13/11/2017), including posi-
tive and negative controls for each of the bacteria studied,
were used for qRT-PCR analysis of P. aeruginosa (RegA),
H. inﬂuenzae (OMP P6), M. catarrhalis (copB), S. pneu-
moniae (alpha-fucosidase gene), S. aureus (FEMB gene).
Genesig’s Manufacturers’ instructions were carefully fol-
lowed for bacterial RT-PCR quantiﬁcation. RT-PCR
cycling conditions were: 95 °C for 5 min (PCR initial
activation step); 40 ampliﬁcation cycles of 95 °C for 5 s
(denaturation) and 60 °C for 10 s (combined annealing/
extension), followed by melting curve analysis to ensure
the speciﬁcity of the PCR ampliﬁcation. For each reaction,
negative controls were run in triplicate, consisting of pri-
mers, PCR Mastermix and sterile water instead of DNA
template. Ampliﬁcation, data acquisition, and cycle thresh-
old (CT) values analysis was performed using the Rotor
Gene Q software (Rotor-Gene Q Series Software 2.0.2).
Data were expressed as copies/ml of collected sputum
from each patient studied.
Routine bacteriological methods for identiﬁcation of
bacteria were used.25 The detection limit for sputum cul-
tures was 103 colony forming units (CFU)xml−1 of each
sampled sputum. A comparative analysis between the tra-
ditional methodology (CFU) and the RT-PCR bacterial
quantitation was also performed.
Quantitation of inﬂammatory cells in
sputum samples
The total number of inﬂammatory and buccal epithelial cells
was quantiﬁed in sputum samples (cells/ml) and cellular types
were counted in each cytospin preparation. The percentage of
neutrophils, eosinophils, macrophages, lymphocytes and squa-
mous epithelial cells was calculated for each subject studied.
ELISA tests for measurement of
mediators
Sputum supernatants were aliquoted and stored at −80 °C
until their use for the ELISA assays that have been sum-
marized in Table S1. ELISA assays were performed in
sixteen patients per group (n=80) consecutively enrolled
in this study. These assays were performed according to
the manufacturers’ instructions.
Statistical analysis
Group data were expressed as mean ± standard deviation
(SD) for functional data and median (range) or interquartile
range (IQR) for morphologic data. Differences between
groups were analyzed using analysis of variance (ANOVA)
for functional data. The ANOVA test was followed by the
unpaired t-test for comparison between groups. The Kruskal-
Wallis test applied for morphologic data, when signiﬁcant,
was followed by the Mann-Whitney U test for comparison
between groups. Correlation coefﬁcients were calculated
using the Spearman rank method. Probability values of
p<0.05 were considered signiﬁcant. Data analysis was per-
formed using the Stat View SE Graphics program (Abacus
Concepts Inc., Berkeley, CA, USA).
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Results
Clinical characteristics of subjects
We obtained and studied sputum samples from 102 subjects:
20 with cigarette smoke-associated stable COPD, 21 AATD-
noT, 20 AATD-AT, 20 CS and 21 CON (Table 1). Cigarette
smoke-associated COPD patients were older than control
subjects (both CS and CON), had a similar history of smok-
ing to CS, and their spirometry values showed mild to severe
bronchial obstruction. Compared to cigarette smoke-asso-
ciated COPD patients, AATD-AT patients were younger,
had a reduced history of smoking, similar spirometry and
DLCO values as well as emphysema grading on high resolu-
tion computed tomography (HRCT) but increased total lung
capacity (TLC) values. AATD-noT patients had intermediate
characteristics between cigarette smoke-associated COPD
and AATD-AT patients. They were of similar age to
AATD-AT patients and thus younger than cigarette smoke-
associated COPD. Their smoking history was similar to
AATD-AT patients, but lower than cigarette smoke-asso-
ciated COPD. They did not show marked airﬂow obstruction
at spirometry and relatively low emphysema grading on
HRCT of the chest, thus differing from both cigarette
smoke-associated COPD and AATD-AT patients, but they
had increased TLC values similarly to AATD-AT patients.
Finally, they had reduced DLCO values, but still higher than
those of cigarette smoke-associated COPD and AATD-AT
patients (Table 1).
All AATD patients had AAT plasma levels below the
normal range. In AATD-AT, circulating AAT levels, mea-
sured just before augmentation therapy treatment, were
lower compared to AATD-noT patients (28.03±18 vs
42.18±25 mg/dl; p=0.0545).
Genotype of AATD patients
The genotypes of AATD-noT patients were: PI*ZZ 8 cases,
PI*SZ 6, PI*ZMwurzburg 1, PI*ZMvarallo 1, PI*ZQbrescia 1,
PI*ZQparma 1, PI*SS 1, PI*Z new variant 1, PI*S new variant
1; the AAT genotypes of AATD-AT were: PI*ZZ 13, PI*SZ
2, PI*ZYorzinuovi 1, PI*SPlowel 1, PI*Q0 granitefallsQ0granitefalls
1, PI*Q0bresciaQ0brescia 1, PI*ZQ0parma 1.
Inﬂammatory cells in the sputum
The results of the histochemical analysis are summarized
in Table 2 and Figure 1A–E. Total sputum inﬂammatory
cells did not differ signiﬁcantly across the ﬁve groups
(Kruskal-Wallis test, p=0.6777). Differential cell counts
reported as percentage, however, were different between
the study groups. Neutrophils percentage (Kruskal-Wallis:
0.0137) was increased in cigarette smoke-associated
COPD patients compared to CON and AATD-AT groups
(Mann-Whitney: p=0.0015 and p=0.0135, respectively),
and was also different from the AATD-noT group
(p=0.0446). The percentage of eosinophils (Kruskal-
Wallis: p=0.0508) tended to be higher in cigarette
smoke-associated COPD, AATD-noT and AATD-AT com-
pared to CON (Mann-Whitney: p=0.0229, p=0.0345 and
p=0.0098, respectively). The percentage of lymphocytes
(Kruskal-Wallis: p=0.0955) showed a higher trend in CS,
cigarette smoke-associated COPD, and AATD-noT com-
pared to CON (Mann-Whitney: p=0.0366, p=0.0141 and
p=0.0439, respectively).
The percentage of macrophages was not statistically
different across the ﬁve groups at the Kruskal-Wallis test
(p=0.0560), even though a higher trend was observed in
CS and AATD-noT compared to CON (Mann-Whitney:
p=0.0050 and p=0.0203, respectively) (Table 2).
Inﬂammatory mediators measured by
ELISA in the sputum supernatants
ELISA data are reported in Table 3 and Figure 2. Table S1
shows the ELISA tests used. CCL3 (MIP1α), CCL5
(RANTES), LTB4 and MPO levels did not differ across the
ﬁve patient groups studied (Figure 2A–D). No signiﬁcant
differences were found in CXCL8 level between the ﬁve
groups (Kruskal-Wallis: (p=0.0881) studied (Figure 2E).
Sputum IL-27 levels in cigarette smoke-associated COPD
were similar to that in AAT-noT, but signiﬁcantly increased
compared to AATD-AT and CON (p=0.0297 and p=0.0136,
respectively).
ELISA tests considerations
Considering patients and control subjects studied by ELISA
tests (n=80, 16 cases for each group), all the signiﬁcant
changes reported when all cases have been studied for
quantitation (n=102, 20–21 cases for each group) of func-
tional data (Table 1), cell count (Table 2) and bacterial load
(Figures 3 and 4) have been maintained. The percentage of
neutrophils was as well signiﬁcantly reduced in AATD-AT
(n=16) patients compared to cigarette smoke-associated
COPD (n=16); M. catarrhalis (copies/ml) and S. pneumo-
niae (copies/ml) were as well reduced in AATD-AT (n=16)
patients compared to cigarette smoke-associated COPD
(n=16) (p=0.050 and p=0.002, respectively).
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Comparison of relevant inﬂammatory
cells and biomarkers in patients with
AATD-noTwith bronchial obstruction
and cigarette smoke-associated COPD
Since 42% of AATD patients not in the augmentation
therapy (9 out of 21 AATD-noT) had a similar bronchial
obstruction when compared to cigarette smoke-associated
COPD patients, we compared them for the relevant inﬂam-
matory markers studied. The number of neutrophils (cells/
ml and percentage), IL-27 and CCL5 proteins were not
signiﬁcantly different in the two groups studied (Mann-
Whitney: p=0.186, p=0.194, p=0.053 and p=0.192, respec-
tively). A slight but signiﬁcant increase of M. catarrhalis
(copies/ml) (p=0.016) and of S. pneumoniae (copies/ml)
(p=0.0125) was observed in cigarette smoke-associated
COPD compared to AATD-noT patients with bronchial
obstruction (n=9). The reasons for this difference need a
more extended analysis involving a higher number of
AATD-noT patients.
Colony-forming units (CFU) in the
sputum
In the group of CON, 20 subjects showed the presence of
normal bacterial ﬂora, and one showed growth of S.
aureus. In the group of CS, 16 subjects showed normal
bacterial ﬂora, 2 showed H. parainﬂuenzae, and 2
showed H. inﬂuenzae. In cigarette smoke-associated
COPD, 11 patients showed normal bacterial ﬂora, 1
patient H. inﬂuenzae, 2 patients S. pneumoniae, 3
patients S. aureus, 1 patient S. aureus plus P. aeruginosa,
1 patient S. aureus plus H. inﬂuenzae, and 1 patient S.
pneumoniae plus H. inﬂuenzae. In AATD-noT, 16
patients had normal bacterial ﬂora, 2 patients P. aerugi-
nosa, 1 patient S. pneumoniae, 1 patient S. aureus, and 1
patient S. aureus plus H. inﬂuenzae. In AATD-AT, 15
patients had normal bacterial ﬂora, 1 patient P. aerugi-
nosa, 1 patient H. inﬂuenzae, 1 patient S. aureus, 1
patient S. aureus plus H. inﬂuenzae, and 1 patient H.
inﬂuenzae plus M. catarrhalis.
Table 1 Clinical characteristics of cigarette smoke-associated chronic obstructive pulmonary disease (COPD), alpha-1 antitrypsin
deﬁciency patients (AATD) and control subjects who provided sputum samples
Control non-
smokers
Control
Smokers
Cigarette smoke-associated
COPD
AATD-noT AATD-AT
Number 21 20 20 21 20
M/F 13/8 11/9 17/3 14/7 14/6
Age (years) 60.33±7.45 61.75±10.29 68.10±7.40#&§ 57.7±10.2 56.9±9.82*
Pack-years – 29.63±10.36& 27.03±26.98§& 12.24
±20.19&#
12.53
±15.0*&#
No/ex/current smokers 21/0/0 0/5/15 0/16/4 7/14/0 5/15/0
FEV1 (L) 3.01±0.70 2.85±0.84 1.41±0.56
&# 2.33±1.15* 1.64±0.95&#
FEV1 (%) 106.0±10.82 102.6±15.85 56.28±25.45
&# 78.67
±32.48*&#
51.5±25.9§&#
FEV1/FVC (%) 80.41±7.67 81.83±9.31 54.81±18.17
&#§ 70.93±21.35* 49.17
±16.47§&#
TLC (L) – – 6.03±0.89 7.39±1.80* 8.14±2.24*
TLC (%) – – 100.2±13.5 115.2±19.38* 121.8±24.39*
RV (L) – – 3.28±0.81 2.89±1.4 4.04±2.05
RV (%) – – 140±36.4 135±54.7 175.6±86.8
RV/TLC% – – 53.54±10.61 37.58±12.21* 52.61±15.40§
DLCO (%) – – 49.8±16.8 80.5±27.8* 56.5±21.9§
DLCO/AV (%) – – 54.6±18.8 87.3±19.8* 61.3±37.09
HRCT grading of
emphysema
– – 2.54±1.02§ 1.52±1.32 2.83±0.78§
Notes: Data are presented as mean ± SD. Ex-smokers had stopped smoking from at least one year. Patients were classiﬁed according to the Global Initiative for Chronic
Obstructive Lung Disease (http://goldcopd.org). ANOVA, *P<0.05 vs cigarette smoke-associated COPD; #p<0.05 vs control smokers; &p<0.05 vs control non-smokers;
§p<0.05 vs AATD-noT.
Abbreviations: AATD-noT, alpha-1 antitrypsin deﬁciency patients not in therapy; AATD-AT, alpha-1 antitrypsin deﬁciency patients in augmentation therapy; M, male; F,
female; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; TLC, total lung capacity; RV, residual volume; DLCO, diffusing capacity of the lung for carbon
monoxide; DLCO/AV, diffusing capacity of the lung for carbon monoxide divided by alveolar volume; ND, not determined.
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Quantiﬁcation of bacterial load in the
sputum
When data were expressed as absolute numbers
(Figure 3) (copies/ml), AATD-NoT and AATD-AT
patients had a signiﬁcantly lower total bacterial load
(16S) than cigarette smoke-associated COPD (p=0.0081
and p=0.0223) (Figure 3A). AATD-noT and AATD-AT
had a lower number of copies/ml of Moraxella catarrha-
lis than cigarette smoke-associated COPD (p=0.0115 and
p=0.0127) (Figure 3B). Cigarette smoke-associated
COPD patients and CS had a higher number of copies/
ml compared to CON (p=0.0009 and 0.0259). AATD-noT
and AATD-AT also had signiﬁcantly fewer copies/ml of
Streptococcus pneumoniae compared to cigarette smoke-
associated COPD (p=0.0013 and p=0.0001). CS also
differed from AATD-AT (p=0.0499) (Figure 3C). No
signiﬁcant differences were observed for Pseudomonas
aeruginosa (Kruskal-Wallis: p=0.0789), Haemophilus
inﬂuenzae (Kruskal-Wallis: p=0.1666) and
Staphylococcus aureus (Kruskal-Wallis: p=0.2246)
across the ﬁve groups studied (Figure 3D–F).
To evaluate changes in the relative proportions of
each bacterium studied, we expressed these data as a
percentage of the total load value constituted by the
sum of the ﬁve bacteria studied (Figure 4). In cigarette
smoke-associated COPD, the percentage of M. catarrha-
lis was higher compared to CON, AATD-noT and AATD-
AT (p=0.0015, p=0.0063 and p=0.0055, respectively).
Again, in cigarette smoke-associated COPD, the percen-
tage of S. pneumoniae was higher compared to CON, CS,
AATD-noT and AATD-AT (p=0.0006, p=0.0094,
p=0.0008 and p<0.0001, respectively). (Figure 4). The
percentages of P. aeruginosa, H. inﬂuenzae and S. aureus
did not signiﬁcantly differ across the ﬁve groups
(Kruskal-Wallis: (p=0.2720, p=0.1598 and p=0.1358,
respectively) (Figure 4).
Correlations between clinical parameters,
number of inﬂammatory cells, signaling
mediators expression and bacterial load
in the sputum
When we grouped patients with cigarette smoke-asso-
ciated COPD (n=20), CS (n=20) and CON (n=21), the
percentage of neutrophils in the sputum was inversely
correlated with FEV1% predicted values (R=−0.301,
p=0.0218) and positively correlated with M. catarrhalisTa
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(copies/ml) (R=0.27, p=0.0344), S. pneumoniae (copies/
ml) (R=0.367, p=0.0045) and P. aeruginosa (copies/ml)
(R=0.319, p=0.0133). The percentage of neutrophils
(n=48) also correlated with CXCL8 (pg/ml) in the super-
natants (R=0.395, p=0.0068) and MPO (ng/ml) (R=0.436,
p=0.0047). However, multiple regression analysis consid-
ering neutrophils (%) as dependent variable and the six
quantiﬁed biomarkers (CCL3, CCL5, CXCL8, IL-27,
LTB4, MPO) as independent variables showed a signiﬁ-
cant positive association with MPO (ng/ml) (R=0.587,
p=0.0007). When we grouped patients with cigarette
smoke-associated COPD (n=20 or 16 for ELISA tests)
and AATD-AT (n=20 or 16 for ELISA tests), M. catar-
rhalis (copies/ml) and S. pneumoniae (copies/ml) signiﬁ-
cantly and positively correlated with the percentage of
neutrophils (R=0.489, p=0.0050 and R=0.570, p=0.0011,
respectively) and IL-27 protein (pg/ml) (R=0.377,
p=0.0423 and R=0.432, p=0.0199, respectively). Scored
emphysema in all patients with AATD (n=41) correlated
signiﬁcantly with FEV1% (R=−0.68, p<0.0001), FEV1/
FVC% (R=−0.58, p=0.0019), lung diffusion capacity of
carbon monoxide (DLCO)% (R=−0.74, p=0.0006) and
with residual volume (RV)% (R=047, p=0.022).
Spontaneous versus induced sputum
analysis and day-to-day variability
In all patients and control subjects studied (n=102) spon-
taneous sputum was obtained from sixty patients and 42
patients underwent to the sputum induction procedure. We
did not ﬁnd signiﬁcant differences between spontaneous
and induced sputum samples for neutrophil % (Mann-
Whitney: p=0.391), IL-27 protein (p=0.777), CCL5 pro-
tein (p=0.569), S. pneumoniae (copies/ml and percentage)
(p=0.645 and p=0.485 respectively) and M. catarrhalis
(copies/ml and percentage) (p=0.650 and 0.424 respec-
tively). The absolute number of neutrophils (cells/ml)
was slightly increased in spontaneous sputum compared
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to the induced one (Mann-Whitney: p=0.034).
Spontaneous sputum was obtained from 15 cigarette
smoke-associated COPD, 15 AATD-AT, 13 AATD-noT, 9
control smokers and 8 control non-smokers. These com-
parisons made in each individual group were all not sig-
niﬁcantly different.
Day-to-day variability has been reported for neutrophil
and some cytokine quantitations in sputum of COPD and
AATD patients.14 The study by Stone’s and coauthors
suggest to optimize the analysis using 2–3 consecutive
sputum samples collected in different days. Stone’s data
were obtained in 12 COPD and 12 AATD patients. We
performed our sputum analysis using a single sample from
each studied patient or control subject using 20–21
patients for each group. Furthermore, data obtained were
considered signiﬁcant only when multiple and paired sta-
tistical tests were signiﬁcant. We believe that the higher
number of patients used in each group (20–21), the statis-
tical analysis adopted and the similar technical approach
(one collection for all cases studied, patients and control
subjects) used for all the ﬁve groups studied may give
reliable results.
Discussion
The main ﬁnding of our study is that the inﬂammatory and
microbiological proﬁles in the lower airways of patients
with AATD differ from those observed in cigarette smoke-
associated COPD. Compared with cigarette smoke-asso-
ciated COPD patients, patients with AATD, whether on AT
or not, had lower amount of neutrophils in sputum and
total load of bacteria (M. catarrhalis and S. pneumonia, in
particular). Cigarette smoking per se affected the micro-
biota composition. Moreover, AATD-AT patients, but not
AAT-noT patients, had decreased IL-27 levels in sputum
compared with cigarette smoke-associated COPD. The
observed differences in inﬂammatory proﬁle among cigar-
ette smoke-associated COPD and AATD-AT patients are
noteworthy as the two groups have a similar clinical and
functional proﬁle.
Patients with AATD-AT were younger than the cigar-
ette smoke-associated COPD group. This is not surprising
considering that airﬂow obstruction and/or pulmonary
emphysema usually appears at a younger age in these
subjects.20 The inclusion criteria for AATD patients were
not restricted to lung function impairment. Thus, in the
AATD-noT group, 66% (13/21) of these patients had
FEV1/FVC% values >70% of predicted, at variance with
lung function data from AATD-AT patients. This and otherTa
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characteristics of the two AATD groups indicate that they
correspond to different time-points in the natural develop-
ment of AATD-related lung disease, passing from the less
severe airway and parenchymal inﬂammatory involvement
in AAT-noT patients to severe COPD in AATD-AT
patients.
Our data conﬁrm an increased sputum neutrophilia in
cigarette smoke-associated COPD in agreement with many
other published reports3–11 whilst the decreased sputum
neutrophil percentage and a trend to decline in absolute
numbers in AATD-AT patients compared to cigarette
smoke-associated COPD also conﬁrm previous
observations.14 However, the mechanisms causing a reduc-
tion in neutrophil accumulation in the lower airways and
their decreased activation after augmentation therapy are
controversial. Neutrophil elastase stimulates epithelial cells
of the lower airways to release CXCL816,26–31,38 and
increased BAL levels of CXCL8 were reported in AATD
patients compared to cigarette smoke-associated COPD14 ;
moreover, colonized AATD or colonized cigarette smoke-
associated COPD patients have increased sputum CXCL8
concentrations compared to the same non-colonized group
of patients.10 However, we did not ﬁnd markedly signiﬁ-
cant differences in sputum CXCL8 levels between AATD-
AT patients and cigarette smoke-associated COPD patients
with a similar degree of airﬂow obstruction, suggesting
that augmentation therapy reduces sputum neutrophilia in
these patients, thus acting with other molecular
mechanisms.
In the present paper, as an original contribution,
AATD-AT patients compared with cigarette smoke-asso-
ciated COPD have a signiﬁcant reduction in sputum IL-27
protein levels, suggesting a role for this cytokine in redu-
cing sputum neutrophilia in these patients. Interestingly,
the sputum levels of IL-27 protein were also positively
correlated with the speciﬁc bacterial load of M. catarrhalis
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and S. pneumoniae (copies/ml) in AATD-AT patients. In
addition, when all AATD patients were grouped together,
sputum IL-27 levels correlated positively with FEV1%
predicted values, suggesting a role for the augmentation
therapy in reducing sputum IL-27.
Monocytes/macrophages and neutrophils are the major
source of IL-27 production during sepsis and blocking of
IL-27 production in neutrophils in vitro reduces bacterial
survival.32 Modulation of neutrophil function by IL-27 is
also reported in intracerebral hemorrhage.33 Interestingly,
IL-27 pre-treatment of neutrophils and monocytes in vitro
decreases CXCL8 production34 and in a model of zymo-
san-induced peritonitis, the administration of IL-27
reduces neutrophil recruitment to the peritoneal cavity.35
We also observed a concomitant reduction of sputum
neutrophil numbers and IL-27 protein levels in AATD-AT
patients compared to cigarette smoke-associated COPD,
with both study groups having a similar degree of airﬂow
obstruction. For the above reasons we speculate that the
reduction in sputum neutrophil numbers may be inﬂu-
enced, at least in part, by IL-27 activity. However, we
cannot exclude that the concomitant decline in both spu-
tum neutrophil and IL-27 levels could also be an effect of
the neutrophil decrement per se since neutrophils synthe-
size IL-27 protein.32
CC-chemokines, in particular CCL3 and CCL5, have
been reported to be involved in the pathogenesis of cigarette
smoke-associated COPD and in the induction of neutrophil
migration and activation.11,36 In the current study, at var-
iance with our previous study performed on bronchial
biopsies,11 we did not observed any signiﬁcant change in
sputum CCL3 and CCL5 levels among the ﬁve groups of
subjects studied. Differences in the release of inﬂammatory
mediators in different compartments of the lower airways
have already been observed in many different chronic
inﬂammatory diseases. Furthermore, we observed no
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pneumoniae was signiﬁcantly increased in cigarette smoke-associated COPD compared to CON, CS, AATD-noT and AATD-AT; CS also had higher values compared to
CON and AATD-AT (C); P. aeruginosa (D); H. inﬂuenzae (E) and S. aureus (F) did not differ signiﬁcantly at the Kruskal-Wallis test.
Abbreviations: CNS, control non-smokers; CS, control smokers; COPD, chronic obstructive pulmonary disease; α1ATDnoT, α1-anti trypsin deﬁciency patients not in
therapy; α1ATDA.T., α1-anti trypsin deﬁciency patients on augmentation therapy.
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signiﬁcant difference in sputum MPO and LTB4 levels
between AATD-AT patients (treated for at least 3 months),
in comparison with cigarette smoke-associated COPD with
a similar degree of obstruction (Figure 2C and D).
When comparing sputum MPO in cigarette smoke-
associated COPD and AATD-noT patients with a similar
degree of airﬂow obstruction there are conﬂicting results
in the literature (Table 4). Whereas most of the previous
studies in the same group of patients have shown a sig-
niﬁcant increase of sputum leukotriene B4 (Table 4). These
differences may be explained by the lack of untreated
AATD patients with severe/very severe COPD in our
study, the differences in the ELISA assays used for mea-
suring these mediators and the length of augmentation
therapy treatment in the different studies (Table 4).
There are few published studies that have investigated
the total and speciﬁc bacterial load and their correlations
with sputum inﬂammation in patients with AATD-AT and
AATD-noT. Both cigarette smoke-associated COPD and
AATD patients in stable phase have increased sputum
CXCL8 and LTB4 levels when colonized compared to
non-colonized patients,10 suggesting a role for bacteria in
increasing neutrophil-related inﬂammation.10 In our study,
only a minority of patients showed sputum CFU for dif-
ferent bacterial species making impossible to directly com-
pare inﬂammatory cells and mediators between colonized
and non-colonized patients. Interestingly, we report here
for the ﬁrst time the absolute (expressed as copies/ml) and
percentage values of the total and speciﬁc bacterial load in
the ﬁve groups of subjects investigated.
We show here that cigarette smoking per se had a clear
effect on microbiota composition, since CS were similar to
CON for total bacterial load (16S) but showed signiﬁ-
cantly increased M catarrhalis and S. pneumoniae when
compared to CON which is in keeping with previous
studies.37 The highest values of total bacterial load were
observed in cigarette smoke-associated COPD. P. aerugi-
nosa showed a trend to be increased in cigarette smoke-
associated COPD, AATD-noT and AATD-AT with respect
to CON conﬁrming earlier studies using different
methods.16,26,38 M. catarrhalis and S. pneumoniae
copies/ml were increased in cigarette smoke-associated
COPD compared to CON and signiﬁcantly decreased in
AATD-AT, having a similar degree of airﬂow obstruction.
CNS (N=21)
A1ATD- No T. (N=21) A1ATD- A.T. (N=20)
CS (N=20)
COPD (N=20)
S. Pueunomiae
4%
P. Aeruginosa
12%
S. Pueunomiae
1% P. Aeruginosa
12%
S Aureus
33%
M. Catarrhalis
1%
H. Influenzae
50%
S Aureus
55%
M. Catarrhalis
1%
H. Influenzae
31%
S. Pueunomiae
0%
P. Aeruginosa
10%
S Aureus
61% M. Catarrhalis
5%
H. Influenzae
24%
S. Pueunomiae
6%
P. Aeruginosa
10%
S Aureus
43%
M. Catarrhalis
4%
H. Influenzae
37%
S. Pueunomiae
17%
P. Aeruginosa
11%
S Aureus
26%
M. Catarrhalis
21%
H. Influenzae
25%
Figure 4 Relative proportions of P. aeruginosa, H. inﬂuenzae, M. catarrhalis, S. aureus and S. pneumoniae in sputum of control non-smokers (CON), control smokers (CS),
cigarette smoke-associated chronic obstructive pulmonary diseased (COPD) patients, α1-anti trypsin deﬁciency not in therapy (AATD-noT) and AATD in augmentation
therapy (AATD-AT) patients. The percentage of M. catarrhalis and S. pneumoniae was higher in cigarette smoke-associated COPD compared to CON. Interestingly,
augmentation therapy in COPD patients with AATD signiﬁcantly reduced the percentage of M. catarrhalis and S. pneumoniae to values close to those observed in CON
subjects.
Abbreviations: CNS, control non-smokers; CS, control smokers; COPD, chronic obstructive pulmonary disease; α1ATDnoT, α1-anti trypsin deﬁciency patients not in
therapy; α1ATDA.T., α1-anti trypsin deﬁciency patients on augmentation therapy.
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This decrement in absolute numbers in AATD-ATwas also
associated to a decreased relative proportion of M. catar-
rhalis and S. pneumoniae when compared to cigarette
smoke-associated COPD. Our observation of a positive
correlation of M. catarrhalis and S. pneumoniae bacterial
load with neutrophil percentage and IL-27 protein in the
sputum of cigarette smoke-associated COPD and AATD-
AT patients suggests a possible inter-relationship between
speciﬁc bacterial load, IL-27 secretion and neutrophil
recruitment. This is in keeping with recent observations
that IL-27 impairs host innate immunity against pneumo-
coccal infection.39 The mechanistic inter-relationship
between neutrophil recruitment, IL-27 production and bac-
terial load, may be worth to be investigated in large con-
trolled clinical trials of augmentation therapy in AATD.
In conclusion, compared to cigarette smoke-associated
COPD, AATD-AT (COPD) patients have a distinct airway
inﬂammatory and microbiological proﬁle. The decreased
sputum bacterial load and IL-27 levels in AATD-AT
patients suggests that augmentation therapy play a role in
these changes. The mechanistic inter-relationship between
neutrophil recruitment, IL-27 production and bacterial
load, may be worth to be investigated in large controlled
clinical trials of augmentation therapy in AATD.
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Methods
Lung function tests and volumes
Pulmonary function tests were performed as previously
described1 according to guideline recommendations.
Pulmonary function tests included measurements of
FEV1 and FEV1/FVC under baseline conditions in all
subjects (6200 Autobox Pulmonary Function Laboratory;
Sensormedics Corp., Yorba Linda, CA, USA). To assess
the reversibility of airﬂow obstruction and post broncho-
dilator functional values, the FEV1 and FEV1/FVC% mea-
surements in the groups of subjects with FEV1/FVC%
≤70% pre-bronchodilator was repeated 20 min after the
inhalation of 0.4 mg of salbutamol.
Reference
1. Di Stefano A, Caramori G, Gnemmi I, et al. Association of increased
CCL5 and CXCL7 chemokine expression with neutrophil activation in
severe stable COPD. Thorax. 2009;64:968–975. doi:10.1136/
thx.2009.113647
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Table S1 Summary of the ELISA assays performed on sputum supernatants
Speciﬁcity Manufacturer website Catalogue code Standard curve sensitivity range Sputum samples
CCL3 Abnova
www.abnova.com
KA0388 15.6–1000 pg/mL Not diluted
CCL5 Abnova
www.abnova.com
KA0411 15.6–1000 pg/mL Not diluted
CXCL8 R&D Systems
www.bio-techne.com
D8000C 31.3–2000 pg/mL Diluted 1:100
IL-27 Cloudclone
www.cloud-clone.us
SEA385Hu 15.6–1000 pg/mL Not diluted
LTB4 R&D Systems
www.bio-techne.com
KGE006B 3.7–2500 pg/ml Diluted 1:10
MPO R&D Systems
www.bio-techne.com
DMYE00B 0.014–10 ng/ml Diluted 1:100
Abbreviations: CCL3, chemokine (CC motif) ligand 3; CCL5, chemokine (CC motif) ligand 5; IL-27, interleukin-27; LTB4, leukotriene-B4; MPO, myeloperoxidase.
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